The TearLab Osmolarity System is intended to measure the osmolarity of human tears to aid in the diagnosis of patients with signs or symptoms of Dry Eye Disease (DED) in conjunction with other methods of clinical evaluation. It is now in a position to be marketed to clinincal facilities in the United States, having received its FDA 510(k) clearance.
This month 40 ophthalmology graduates from all over the globe will converge on Lugano, Switzerland at the European School for Advanced Studies in Ophthalmology (ESASO) to embark on a brand new post-graduate degree which will give them access to world leaders and experts in a variety of ophthalmic fields.
The 9th Euretina Congress took place during May in Nice, France and was attended, according to the organisers, by around 1700 delegates. This was a seminal event and will be the last of its kind as next year it will join forces with ESCRS (European Society of Cataract and Refractive Surgeons) in Paris from 2–8 September.
The cataract surgery technology landscape including pipeline products at varying development stages comes under scrutiny in a new report released this month.
Results of the evaluation of two-year post-surgical safety and efficacy of canaloplasty to treat open angle glaucoma (OAG) have been published in the Journal of Cataract and Refractive Surgery. Dr Richard A Lewis et al., concluded that the procedure was safe and effective in reducing IOP in adult OAG patients.
Novagali Pharma, the French pharmaceutical ophthalmic company, is to conduct a Phase III clinical trial of Catioprost (Nova21027) its Investigational New Drug Application (IND).
Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.
Non governmental organisations have come together to draw attention to the inequalities in eye care for women worldwide.
The world's largest eye bank, The Tampa Lions Eye Institute for Transplant and Research, Inc. in Florida, which has supplied over 30,000 corneas for transplant and 50,000 eyes for research worldwide over the past 30 years, is to open a state-of-the-art research facility.
A diabetic retinopathy (DR) progression biomarker software has been developed with the research institute AIBILI (Association for Biomedical Research and Innovation in Light and Image) and Critical Health.
Central retinal vein occlusion (CRVO) is caused by obstruction of the central retinal vein that that leads to a back up of blood and fluid in the retina, resulting in retinal injury and loss of vision.
Findings, reported online this week,in advance of print in the Proceedings of the National Academy of Sciences (PNAS), are suggesting that the protein kinase JNK1 may have a key role in the development of retinopathy in premature babies.
Three professors from the UCL Institute of Ophthalmology are to become fellows of the Association for Research in Vision and Ophthalmology (ARVO) in its first honours list.
A new collaboration between Oxford BioMedica and Sanofi-Aventis is to develop and commercialise gene therapy treatments for retinal degenerative diseases such as Stargardt disease, the form of early-onset macular degeneration and Usher syndrome, a relatively rare genetic disease where sufferers are born deaf and lose vision within the first 10 years of life.
Ophthotech Corp. has announced positive results of a phase I clinical study evaluating E10030, its novel anti-platelet derived growth factor (anti-PDGF) in conjunction with an anti-vascular endothelial growth factor (anti-VEGF), to treat wet age-related macular degeneration (wet AMD).
Merck & Co., Inc. and Santen Pharmaceutical Co., Ltd., have agreed a worldwide licensing agreement for tafluprost, a prostaglandin analogue under investigation in the US.
Patients suffering from AMD have experienced long-term benefits from using the Macular Health vitamin supplement following the second phase of the Multifocal Electroretinogram (MERG) study at the Callahan Eye Foundation Hospital at the University of Alabama Birmingham (US).
An OTEurope story we ran a couple of weeks ago clearly resonated with reader, Peter Raus in Belgium. Read on to see what he thought.
Visiogen is reporting significant progress in the development of the Synchrony IOL, including the completion of the US phase III study, the formation of Visiogen Europe GmbH and the commencement of commercialization in Europe.
Positive interim data results from the Phase II trial of OT-551 to treat geographic atrophy (GA), an advanced form of AMD, have been announced by Othera Pharmaceuticals Inc.
A study comparing pain perception during cataract surgery with and without the use of lidocaine.
A recent survey looked at how doctors adopt and use new technology, including the internet and found that overall an increasing amount of their time is being spent online and access to the most up-to-date online medical and pharmaceutical resources plays and increasingly important role.
A news round-up, including highlights from this year's ASCRS.
From Facebook to Twitter, individuals are embracing the opportunity to participate in online publishing at an unprecendented rate. Communities of users interact globally, minute-to-minute within huge databases of content that they themselves create.
A comparative study of three presbyopia-correcting lenses demonstrates that aspheric lenses offer superior performance over other designs.
Technolas Perfect Vision is the new company name for the joint venture between Bausch & Lomb and 20/10 Perfect Vision AG that will focus on laser vision correction.
An angiostatic cortisene, Anercortave Acetate (AA), may prove to be the first treatment modality for open-angle glaucoma, which only needs to be administered every three months.
A look at how to introduce canaloplasty into your surgery; experience from two doctors.
Foveal thickness and macular volume decrease after phaco in eyes with diabetic macular oedema, with changes even more pronounced in patients with diabetic retinopathy.
Assessing whether certain surgical methods can minimize exposing the eye to oxidation during phacoemulsification/